NPS Pharmaceuticals Inc (NPSP)

45.97
0.01 0.02
Prev Close 45.96
Open 45.96
Day Low/High 45.95 / 45.99
52 Wk Low/High 22.11 / 46.01
Volume 9.49M
Avg Volume 4.75M
Exchange
Shares Outstanding 108.58M
Market Cap 4.99B
EPS -0.08
Div & Yield N.A. (N.A)
3 Biotech Stocks Spiking on Big Volume

3 Biotech Stocks Spiking on Big Volume

Unusual volume can signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

Ask SUT

David Peltier answers subscribers' questions about two different model portfolio stocks.

'Mad Money' Lightning Round: I Believe in Advanced Micro Devices

'Mad Money' Lightning Round: I Believe in Advanced Micro Devices

Cramer is riding with Hertz Global Holdings but is avoiding Tenet Healthcare.

Jim Cramer's 'Mad Money' Recap: A Down Day for the Market

Jim Cramer's 'Mad Money' Recap: A Down Day for the Market

Professional investors with cash on hand dream of days like today, but the price wasn't right for Cramer.

The Best Biotech CEO of 2013 is...

The Best Biotech CEO of 2013 is...

Bob Hugin of Celgene tops a highly qualified field of nominees to win this year's Best Biotech CEO award.

NPS Pharmaceuticals To Present At Oppenheimer Healthcare Conference

NPS Pharmaceuticals To Present At Oppenheimer Healthcare Conference

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) will present at the Oppenheimer 24 th Annual Healthcare Conference in New York on Tuesday, December 10, 2013 at 9:10 a.

NPS Pharmaceuticals To Webcast Investor And Analyst Event

NPS Pharmaceuticals To Webcast Investor And Analyst Event

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) today announced that it will host an Investor and Analyst Event for its research analysts and institutional investors on Friday, December 6 at 8:30 a.

Best Biotech CEO of 2013: Your Vote Counts

Best Biotech CEO of 2013: Your Vote Counts

The CEOs from NPS Pharma, Onyx Pharma, Bristol-Myers Squibb, Celgene and Ligand Pharma vie for the coveted title of Best Biotech CEO.

2014 FDA Drug Approval Decision Calendar

2014 FDA Drug Approval Decision Calendar

Here's a list of 34 FDA drug approval decisions and scheduled advisory panels from December 31 through October 2014.

NPS Pharmaceuticals Larger Than S&P 500 Component Abercrombie & Fitch

NPS Pharmaceuticals Larger Than S&P 500 Component Abercrombie & Fitch

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component NPS Pharmaceuticals Inc. was identified as having a larger market cap than the smaller end of the S&P 500, for example Abercrombie & Fitch Co.

NPS Pharmaceuticals To Present At Deutsche Bank BioFEST Conference

NPS Pharmaceuticals To Present At Deutsche Bank BioFEST Conference

NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) will present at the 2013 Deutsche Bank BioFEST Conference in Boston on Tuesday, December 3, 2013 at 1:40 p.

NPS Pharmaceuticals Named One Of New Jersey’s 50 Fastest Growing Companies By NJBIZ

NPS Pharmaceuticals Named One Of New Jersey’s 50 Fastest Growing Companies By NJBIZ

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that it has been named one of...

NPS Pharmaceuticals’ President And CEO Dr. Francois Nader Receives Ernst & Young National Entrepreneur Of The Year® 2013 Award In The Life Sciences Category

NPS Pharmaceuticals’ President And CEO Dr. Francois Nader Receives Ernst & Young National Entrepreneur Of The Year® 2013 Award In The Life Sciences Category

NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that president and chief ...

NPS Pharmaceuticals Announces FDA Acceptance Of Supplemental New Drug Application For Gattex® (Teduglutide [rDNA Origin]) For Injection

NPS Pharmaceuticals Announces FDA Acceptance Of Supplemental New Drug Application For Gattex® (Teduglutide [rDNA Origin]) For Injection

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that the U.

Ratings Changes Today

Upgrades: AGO, BBGI, BKMU, CODI, EME, FONR, LPI Downgrades: ADNC, AUQ, CYD, DATE, DPZ, EROC, FSP, LBTYB, LBTYK, LYV, NPSP, RLJ, SF, SHO Initiations: ANFI, GALE, RLGY Read on to get TheStreet Quant Ratings' detailed report:

NPS Pharmaceuticals To Present At Jefferies Global Healthcare Conference

NPS Pharmaceuticals To Present At Jefferies Global Healthcare Conference

NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) is scheduled to present at the Jefferies 2013 Global Healthcare Conference in London on Thursday, November 21, 2013 at 8:40 a.

Today's Dead Cat Bounce Stock: NPS Pharmaceuticals (NPSP)

Today's Dead Cat Bounce Stock: NPS Pharmaceuticals (NPSP)

Trade-Ideas LLC identified NPS Pharmaceuticals (NPSP) as a "dead cat bounce" (down big yesterday but up big today) candidate

Jim Cramer's 'Mad Money' Recap: Tesla Didn't Execute

Jim Cramer's 'Mad Money' Recap: Tesla Didn't Execute

Stocks need execution as well as growth to succeed, Cramer says.

NPS Pharmaceuticals Reports Third Quarter 2013 Financial Results And Provides Business Update

NPS Pharmaceuticals Reports Third Quarter 2013 Financial Results And Provides Business Update

NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, reported its results for the third quarter.

Today's Perilous Reversal Stock: NPS Pharmaceuticals (NPSP)

Today's Perilous Reversal Stock: NPS Pharmaceuticals (NPSP)

Trade-Ideas LLC identified NPS Pharmaceuticals (NPSP) as a "perilous reversal" (up big yesterday but down big today) candidate

NPS Pharmaceuticals To Report Third Quarter 2013 Financial Results

NPS Pharmaceuticals To Report Third Quarter 2013 Financial Results

NPS Pharmaceuticals, Inc. (Nasdaq:NPSP) announced today that it will report its third quarter 2013 financial results on Wednesday, November 6, 2013 at approximately 8:00 a.

NPS Pharmaceuticals Submits Biologic License Application To The U.S. Food And Drug Administration For Natpara® In Hypoparathyroidism

NPS Pharmaceuticals Submits Biologic License Application To The U.S. Food And Drug Administration For Natpara® In Hypoparathyroidism

NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that the company has submitted...

Catalyst Pharma: Orphan Drug Poseur, Profiteer

Catalyst Pharma: Orphan Drug Poseur, Profiteer

Catalyst's lead drug for the rare LEMS disease is already given away for free by a competitor.

New Data From STEPS 2 Support The Long Term Use Of Gattex® (Teduglutide [rDNA Origin]) For Injection In Adult Patients With Short Bowel Syndrome

New Data From STEPS 2 Support The Long Term Use Of Gattex® (Teduglutide [rDNA Origin]) For Injection In Adult Patients With Short Bowel Syndrome

NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced new findings from its STEPS 2...

Trade-Ideas: NPS Pharmaceuticals (NPSP) Is Today's "Perilous Reversal" Stock

Trade-Ideas: NPS Pharmaceuticals (NPSP) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified NPS Pharmaceuticals (NPSP) as a "perilous reversal" (up big yesterday but down big today) candidate

Jim Cramer's 'Mad Money' Recap: A Glimmer of Hope

Jim Cramer's 'Mad Money' Recap: A Glimmer of Hope

They're negotiating in Washington, and that gave the markets something to cheer about, Cramer says. But that may not last.

[video] Quick Take: Work That Cash!

[video] Quick Take: Work That Cash!

Some widely held stocks have dropped 10% in the past 24 hours. Portfolio Manager David Peltier discusses what he's buying.

Putting Cash to Work

Putting Cash to Work

Some widely held stocks have dropped 10% in the past 24 hours. Portfolio Manager David Peltier discussed what he's buying.

Trade-Ideas: NPS Pharmaceuticals (NPSP) Is Today's "Water-Logged And Getting Wetter" Stock

Trade-Ideas: NPS Pharmaceuticals (NPSP) Is Today's "Water-Logged And Getting Wetter" Stock

Trade-Ideas LLC identified NPS Pharmaceuticals (NPSP) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

New Findings From The REPLACE Study Suggest Natpara Has A Beneficial Effect On Bone Health In Patients With Hypoparathyroidism

New Findings From The REPLACE Study Suggest Natpara Has A Beneficial Effect On Bone Health In Patients With Hypoparathyroidism

NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, yesterday presented findings from the ...